Breaking News

EyePoint Pharmaceuticals Breaks Ground on New Manufacturing Facility

Includes pharmaceutical production suites for clinical supply and commercial scale manufacturing of approved products.

RP Masiello is building a new manufacturing facility for EyePoint Pharmaceuticals, a company that develops new treatments and drug-delivery systems for challenging eye diseases, including macular degeneration, the leading cause of vision loss among adults. The building is expected to be completed in late 2024. EyePoint Pharmaceuticals will be the sole tenant in the new building. The 40,000 sq.-ft. building, located on Commerce Drive in Northbridge, MA, will be designed and constructed to meet...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters